Moreover, the 36-month beta value for CDLX is 1.17. Analysts have varying opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 5 as “hold,” and 0 as “sell.”
The public float for CDLX is 49.56M and currently, short sellers hold a 16.79% of that float. On May 02, 2025, CDLX’s average trading volume was 1.02M shares.
CDLX) stock’s latest price update
The stock of Cardlytics Inc (NASDAQ: CDLX) has increased by 9.97 when compared to last closing price of 1.50. Despite this, the company has experienced a 9.60% gain in its stock price over the last five trading sessions. businesswire.com reported 2025-04-25 that ATLANTA–(BUSINESS WIRE)–Cardlytics, Inc. (NASDAQ: CDLX) today announced that on April 24, 2025, the Compensation Committee of Cardlytics’ Board of Directors granted an aggregate of 124,050 restricted stock units of Cardlytics to 11 newly hired employees. The restricted stock units were granted as material inducements to employment with Cardlytics in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted under the Cardlytics, Inc. 2022 Inducement Plan (the “2022 Inducement Plan”). For.
CDLX’s Market Performance
Cardlytics Inc (CDLX) has experienced a 9.60% rise in stock performance for the past week, with a -9.07% drop in the past month, and a -45.92% drop in the past quarter. The volatility ratio for the week is 10.65%, and the volatility levels for the past 30 days are at 12.58% for CDLX. The simple moving average for the last 20 days is 12.15% for CDLX stock, with a simple moving average of -53.76% for the last 200 days.
Analysts’ Opinion of CDLX
Many brokerage firms have already submitted their reports for CDLX stocks, with Evercore ISI repeating the rating for CDLX by listing it as a “In-line.” The predicted price for CDLX in the upcoming period, according to Evercore ISI is $4 based on the research report published on October 11, 2024 of the previous year 2024.
Northland Capital, on the other hand, stated in their research note that they expect to see CDLX reach a price target of $5. The rating they have provided for CDLX stocks is “Market Perform” according to the report published on August 16th, 2024.
BofA Securities gave a rating of “Underperform” to CDLX, setting the target price at $3.50 in the report published on August 15th of the previous year.
CDLX Trading at -14.57% from the 50-Day Moving Average
After a stumble in the market that brought CDLX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -89.58% of loss for the given period.
Volatility was left at 12.58%, however, over the last 30 days, the volatility rate increased by 10.65%, as shares surge +5.05% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -43.75% lower at present.
During the last 5 trading sessions, CDLX rose by +10.26%, which changed the moving average for the period of 200-days by -81.35% in comparison to the 20-day moving average, which settled at $1.4765. In addition, Cardlytics Inc saw -55.39% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CDLX starting from Lynton Nicholas Hollmeyer, who sale 303 shares at the price of $1.51 back on Apr 22 ’25. After this action, Lynton Nicholas Hollmeyer now owns 102,119 shares of Cardlytics Inc, valued at $458 using the latest closing price.
Lynton Nicholas Hollmeyer, the Officer of Cardlytics Inc, proposed sale 303 shares at $1.51 during a trade that took place back on Apr 22 ’25, which means that Lynton Nicholas Hollmeyer is holding shares at $458 based on the most recent closing price.
Stock Fundamentals for CDLX
Current profitability levels for the company are sitting at:
- -0.7 for the present operating margin
- 0.44 for the gross margin
The net margin for Cardlytics Inc stands at -0.68. The total capital return value is set at -0.8. Equity return is now at value -184.87, with -39.16 for asset returns.
Based on Cardlytics Inc (CDLX), the company’s capital structure generated 0.76 points at debt to capital in total, while cash flow to debt ratio is standing at -0.04. The debt to equity ratio resting at 3.17. The interest coverage ratio of the stock is -21.97.
Currently, EBITDA for the company is -152.53 million with net debt to EBITDA at -1.02. When we switch over and look at the enterprise to sales, we see a ratio of 0.87. The receivables turnover for the company is 2.6for trailing twelve months and the total asset turnover is 0.71. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.19.
Conclusion
To wrap up, the performance of Cardlytics Inc (CDLX) has been bad in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
